IL129686A - Method for producing recombinant virus - Google Patents

Method for producing recombinant virus

Info

Publication number
IL129686A
IL129686A IL12968697A IL12968697A IL129686A IL 129686 A IL129686 A IL 129686A IL 12968697 A IL12968697 A IL 12968697A IL 12968697 A IL12968697 A IL 12968697A IL 129686 A IL129686 A IL 129686A
Authority
IL
Israel
Prior art keywords
recombinant virus
producing recombinant
producing
virus
concerns
Prior art date
Application number
IL12968697A
Other languages
English (en)
Other versions
IL129686A0 (en
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9497899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL129686(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL129686A0 publication Critical patent/IL129686A0/xx
Publication of IL129686A publication Critical patent/IL129686A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pens And Brushes (AREA)
  • Materials For Medical Uses (AREA)
IL12968697A 1996-11-22 1997-11-18 Method for producing recombinant virus IL129686A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9614278A FR2756297B1 (fr) 1996-11-22 1996-11-22 Procede de production de virus recombinants
PCT/FR1997/002073 WO1998022607A1 (fr) 1996-11-22 1997-11-18 Procede de production de virus recombinants

Publications (2)

Publication Number Publication Date
IL129686A0 IL129686A0 (en) 2000-02-29
IL129686A true IL129686A (en) 2005-12-18

Family

ID=9497899

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12968697A IL129686A (en) 1996-11-22 1997-11-18 Method for producing recombinant virus

Country Status (18)

Country Link
US (2) US6387670B1 (https=)
EP (1) EP0946741B1 (https=)
JP (1) JP4686670B2 (https=)
KR (1) KR100719645B1 (https=)
AT (1) ATE317908T1 (https=)
AU (1) AU731106B2 (https=)
BR (1) BR9713388B1 (https=)
CA (1) CA2271438C (https=)
CZ (1) CZ293947B6 (https=)
DE (1) DE69735274T2 (https=)
ES (1) ES2260803T3 (https=)
FR (1) FR2756297B1 (https=)
HU (1) HU224713B1 (https=)
IL (1) IL129686A (https=)
NO (2) NO323937B1 (https=)
SK (1) SK286900B6 (https=)
WO (1) WO1998022607A1 (https=)
ZA (1) ZA9710516B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501042A (ja) * 1999-05-27 2003-01-14 ジェノボ， インコーポレイテッド 非哺乳動物ウイルス由来のキャリアベクターを使用する、組換えウイルスの産生のための組成物および方法
US6793926B1 (en) * 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
WO2000073424A1 (en) * 1999-05-28 2000-12-07 Mount Sinai School Of Medicine A novel baculovirus/adenovirus hybrid vector for the rescue, production and titration of high-capacity adenovirus amplicon vectors
GB9919409D0 (en) * 1999-08-18 1999-10-20 Univ Oxford Brookes Baculovirus expression system
WO2004020605A2 (en) * 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
GB0702694D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Vectors
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP2249950B1 (en) * 2008-03-05 2014-10-15 Council of Scientific & Industrial Research A polymeric hybrid membrane
EP2287323A1 (en) 2009-07-31 2011-02-23 Association Institut de Myologie Widespread gene delivery to the retina using systemic administration of AAV vectors
EP2292781A1 (en) 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
CN102884196B (zh) * 2010-04-01 2015-05-06 肖卫东 重组病毒载体的结构及其制备
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
WO2013170078A1 (en) 2012-05-09 2013-11-14 Oregon Health & Science University Adeno associated virus plasmids and vectors
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US20150182637A1 (en) 2012-06-21 2015-07-02 Association Institut De Myologie Widespread gene delivery of gene therapy vectors
WO2015031686A1 (en) * 2013-08-30 2015-03-05 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
US10538571B2 (en) 2017-11-27 2020-01-21 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
US20190256867A1 (en) 2018-02-01 2019-08-22 Homology Medicines, Inc. Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
JP7244547B2 (ja) 2018-02-19 2023-03-22 ホモロジー・メディシンズ・インコーポレイテッド Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
US12215338B2 (en) 2018-05-08 2025-02-04 Neuracle Science Co., Ltd. Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies
WO2020160508A1 (en) 2019-01-31 2020-08-06 Oregon Health & Science University Methods for using transcription-dependent directed evolution of aav capsids
AU2020334147A1 (en) 2019-08-21 2022-03-31 Trames Bio, Inc. Compositions and methods for neurological diseases
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
CA3195177A1 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
US20250296996A1 (en) 2022-04-29 2025-09-25 Broadwing Bio, Inc. Angiopoietin-related protein 7-specific antibodies and uses thereof
EP4514844A1 (en) 2022-04-29 2025-03-05 Broadwing Bio LLC Complement factor h related 4-specific antibodies and uses thereof
KR20250018169A (ko) 2022-04-29 2025-02-04 브로드윙 바이오 엘엘씨 이중특이적 항체 및 안구 질환의 치료 방법
WO2024227154A1 (en) 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof
WO2025040613A1 (en) * 2023-08-21 2025-02-27 Vector Biopharma Ag Cell line for production of helper-dependent adenoviruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2755817B2 (ja) * 1988-11-14 1998-05-25 アメリカ合衆国 パルボウイルスキャプシド
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
JPH10506530A (ja) * 1994-09-23 1998-06-30 ザ ジェネラル ホスピタル コーポレーション 哺乳類細胞において外来遺伝子を発現する非哺乳類ｄｎａウイルスの使用

Also Published As

Publication number Publication date
NO323937B1 (no) 2007-07-23
FR2756297A1 (fr) 1998-05-29
DE69735274D1 (de) 2006-04-20
BR9713388A (pt) 2000-03-21
HU224713B1 (en) 2006-01-30
NO992464D0 (no) 1999-05-21
ZA9710516B (en) 1998-06-10
CA2271438A1 (fr) 1998-05-28
DE69735274T2 (de) 2006-10-12
ES2260803T3 (es) 2006-11-01
CZ182299A3 (cs) 1999-08-11
AU5226198A (en) 1998-06-10
CA2271438C (fr) 2010-10-26
ATE317908T1 (de) 2006-03-15
EP0946741B1 (fr) 2006-02-15
FR2756297B1 (fr) 1999-01-08
AU731106B2 (en) 2001-03-22
SK286900B6 (sk) 2009-07-06
NO2013009I1 (no) 2013-04-29
KR20000057202A (ko) 2000-09-15
EP0946741A1 (fr) 1999-10-06
WO1998022607A1 (fr) 1998-05-28
US20030022356A1 (en) 2003-01-30
BR9713388B1 (pt) 2009-01-13
KR100719645B1 (ko) 2007-05-17
CZ293947B6 (cs) 2004-08-18
IL129686A0 (en) 2000-02-29
HUP0001762A2 (hu) 2000-09-28
SK66699A3 (en) 2000-02-14
JP4686670B2 (ja) 2011-05-25
JP2001503993A (ja) 2001-03-27
US6387670B1 (en) 2002-05-14
HUP0001762A3 (en) 2002-01-28
NO992464L (no) 1999-06-23

Similar Documents

Publication Publication Date Title
IL129686A0 (en) Method for producing recombinant virus
IL125124A0 (en) Dimeric forms of the protein fapalpha and uses thereof
ZA984380B (en) Refractory material based on chromium corundum chromium-corundum brick and use of the brick
DE69534778D1 (en) Cathepsin-02-protease
EP2270047A3 (en) Anti-C5 antibodies and their therapeutic uses
WO1996017072A3 (en) Recombinant alphavirus vectors
EP1508574A3 (en) Long wavelength engineered fluorescent proteins
MY125565A (en) Intermediates and process for preparing olanzapine
ZA972681B (en) Improved puzzle-lock compression ring.
AU1534195A (en) Quinazoline-2,4-diones
ZA975077B (en) Modulation of LC132 (opioid-like) receptor function.
ZA98755B (en) Substituted hydroxy-anilino derivatives of cyclobutane-3,4-diones.
CA2308386A1 (en) Method for digital signing of a message
IL117503A0 (en) Optical resonator
ZA959630B (en) Diaminocyclobutene-3, 4-diones.
AU4088097A (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta(b)benzofurans
EP1082126A4 (en) NEW PEPTIDES
AU3893493A (en) Micro-organisms, preparation method therefor and uses thereof
IL135516A0 (en) Process for n-desmethylating erythromycins and derivatives thereof
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
AU7773987A (en) R.f. glow discharge constant current source
ZA972396B (en) An enzyme combination.
SE9604093D0 (sv) Filter
ZA952756B (en) Alkoxy-alkyl-substituted 1h-3-aryl-pyrrolidine-2,4-diones
ZA978233B (en) The use of protein as anti-retroviral agents.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired